Literature DB >> 9001241

Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase.

H A Kim1, B Ling, N Ratner.   

Abstract

We have developed a potential model of Schwann cell tumor formation in neurofibromatosis type 1 (NF1). We show that mouse Schwann cells heterozygous or null at Nf1 display angiogenic and invasive properties, mimicking the behavior of Schwann cells from human neurofibromas. Mutations at Nf1 are insufficient to promote Schwann cell hyperplasia. Here we show that Schwann cell hyperplasia can be induced by protein kinase A activation in mutant cells. Removal of serum from the culture medium also stimulates hyperplasia, but only in some mutant cells. After serum removal, clones of hyperproliferating Schwann cells lose contact with axons in vitro, develop growth factor-independent proliferation, and exhibit decreased expression of the cell differentiation marker P0 protein; hyperproliferating cells develop after a 1-week lag in Schwann cells heterozygous at Nf1. The experiments suggest that events subsequent to Nf1 mutations are required for development of Schwann cell hyperplasia. Finally, an anti-Ras farnesyl protein transferase inhibitor greatly diminished both clone formation and hyperproliferation of null mutant cells, but not invasion; farnesyl transferase inhibitors could be useful in treating benign manifestations of NF1.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9001241      PMCID: PMC231813          DOI: 10.1128/MCB.17.2.862

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  71 in total

Review 1.  Growth factors and angiogenesis.

Authors:  R J Schott; L A Morrow
Journal:  Cardiovasc Res       Date:  1993-07       Impact factor: 10.787

2.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

Authors:  J Rak; Y Mitsuhashi; L Bayko; J Filmus; S Shirasawa; T Sasazuki; R S Kerbel
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

3.  Inhibition of the EGF-activated MAP kinase signaling pathway by adenosine 3',5'-monophosphate.

Authors:  J Wu; P Dent; T Jelinek; A Wolfman; M J Weber; T W Sturgill
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

4.  Inhibition by cAMP of Ras-dependent activation of Raf.

Authors:  S J Cook; F McCormick
Journal:  Science       Date:  1993-11-12       Impact factor: 47.728

5.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

Authors:  T Jacks; T S Shih; E M Schmitt; R T Bronson; A Bernards; R A Weinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

6.  Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues.

Authors:  C I Brannan; A S Perkins; K S Vogel; N Ratner; M L Nordlund; S W Reid; A M Buchberg; N A Jenkins; L F Parada; N G Copeland
Journal:  Genes Dev       Date:  1994-05-01       Impact factor: 11.361

7.  Regulation of basic fibroblast growth factor mRNA expression in rat C6 glioma cells.

Authors:  P P Powell; M Klagsbrun
Journal:  Exp Cell Res       Date:  1993-12       Impact factor: 3.905

8.  Loss of neurofibromin results in neurotrophin-independent survival of embryonic sensory and sympathetic neurons.

Authors:  K S Vogel; C I Brannan; N A Jenkins; N G Copeland; L F Parada
Journal:  Cell       Date:  1995-09-08       Impact factor: 41.582

9.  Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.

Authors:  N Yan; C Ricca; J Fletcher; T Glover; B R Seizinger; V Manne
Journal:  Cancer Res       Date:  1995-08-15       Impact factor: 12.701

10.  TP53 mutations are frequent in malignant NF1 tumors.

Authors:  E Legius; H Dierick; R Wu; B K Hall; P Marynen; J J Cassiman; T W Glover
Journal:  Genes Chromosomes Cancer       Date:  1994-08       Impact factor: 5.006

View more
  41 in total

1.  Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1.

Authors:  H A Kim; N Ratner; T M Roberts; C D Stiles
Journal:  J Neurosci       Date:  2001-02-15       Impact factor: 6.167

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

Review 3.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

4.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

5.  Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Authors:  Ami V Patel; David Eaves; Walter J Jessen; Tilat A Rizvi; Jeffrey A Ecsedy; Mark G Qian; Bruce J Aronow; John P Perentesis; Eduard Serra; Timothy P Cripe; Shyra J Miller; Nancy Ratner
Journal:  Clin Cancer Res       Date:  2012-07-18       Impact factor: 12.531

6.  Schweinfurthin A selectively inhibits proliferation and Rho signaling in glioma and neurofibromatosis type 1 tumor cells in a NF1-GRD-dependent manner.

Authors:  Thomas J Turbyville; Demirkan B Gürsel; Robert G Tuskan; Jessica C Walrath; Claudia A Lipschultz; Stephen J Lockett; David F Wiemer; John A Beutler; Karlyne M Reilly
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

7.  A role for Pak protein kinases in Schwann cell transformation.

Authors:  Y Tang; S Marwaha; J L Rutkowski; G I Tennekoon; P C Phillips; J Field
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

8.  NF1 loss disrupts Schwann cell-axonal interactions: a novel role for semaphorin 4F.

Authors:  Simona Parrinello; Luke A Noon; Marie C Harrisingh; Patrick Wingfield Digby; Laura H Rosenberg; Catherine A Cremona; Pedro Echave; Adrienne M Flanagan; Luis F Parada; Alison C Lloyd
Journal:  Genes Dev       Date:  2008-12-01       Impact factor: 11.361

9.  A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis.

Authors:  Carlos Riveros; Drew Mellor; Kaushal S Gandhi; Fiona C McKay; Mathew B Cox; Regina Berretta; S Yahya Vaezpour; Mario Inostroza-Ponta; Simon A Broadley; Robert N Heard; Stephen Vucic; Graeme J Stewart; David W Williams; Rodney J Scott; Jeanette Lechner-Scott; David R Booth; Pablo Moscato
Journal:  PLoS One       Date:  2010-12-01       Impact factor: 3.240

10.  Role of TC21/R-Ras2 in enhanced migration of neurofibromin-deficient Schwann cells.

Authors:  Yuan Huang; Fatima Rangwala; Patricia C Fulkerson; Bo Ling; Erin Reed; Adrienne D Cox; John Kamholz; Nancy Ratner
Journal:  Oncogene       Date:  2004-01-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.